title: Timing of coronary stent thrombosis in patients treated with prophylactic tirofiban.
abstract: BACKGROUND
  Acute and subacute stent thromboses (ASST) are the major thrombotic complications of coronary stenting. The time course of ASST seems to be related to the type of antithrombotic therapy (four days in patients treated with aspirin and coumadin compared to 12 hours with the use of aspirin and ticlopidine). In this report, we compared the timing of ASST in patients treated with aspirin, ticlopidine/clopidogrel, heparin and tirofiban with that in patients treated with the same drugs but without tirofiban.
  
  
  METHODS
  Retrospective analysis of the Hermann intervention database between January 1997 and October 1999 was performed. We identified 13 patients who required reintervention in the first week after a successful coronary stenting ( 1 stent). Four patients were treated with tirofiban (Group 1) and 9 were not (Group 2).
  
  
  RESULTS
  The median time from stent deployment to ASST was 7 hours (interquartile range, 2.5Eth 33 hours) in group 2 compared to 84.5 hours (interquartile range, 56Eth 124.5 hours) in group 1. The mean time from stent deployment to ASST was 90.3 +/- 43.1 hours in group 1 versus 12.8 +/- 15.3 hours in group 2 (p = 0.0005). All episodes of ASST occurred 3 days in patients treated with tirofiban, whereas they occurred in the first 2 days in all patients not treated with tirofiban.
  
  
  CONCLUSIONS
  Prophylactic tirofiban treatment delays the time to stent thrombosis after successful coronary artery stent implantation for more than two days. Patients at high risk for stent thrombosis treated with short-acting glycoprotein IIb/IIIa platelet receptor inhibitors may warrant close follow-up during the first week after stenting.
authors.affiliation: Cardiology Division, U.T.H.S.C.-Houston, P.O. Box 20708, Houston, TX 77225-0708, USA.
authors.forename: A R
authors.initials: AR
authors.lastname: Assali
authors.forename: S
authors.initials: S
authors.lastname: Sdringola
authors.forename: M
authors.initials: M
authors.lastname: Ghani
authors.forename: L A
authors.initials: LA
authors.lastname: Westbrook
authors.forename: H V
authors.initials: HV
authors.lastname: Anderson
authors.forename: G
authors.initials: G
authors.lastname: Schroth
authors.forename: K
authors.initials: K
authors.lastname: Fujise
authors.forename: R W
authors.initials: RW
authors.lastname: Smalling
authors.forename: O R
authors.initials: OR
authors.lastname: Rosales
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy; D005260:Female; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011475:Prosthesis Failure; D012189:Retrospective Studies; D015607:Stents; D013997:Time Factors; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban